Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbidol in Reducing AECOPD Frequency
NCT03851991Phase 4Completed
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of umifenovir in chronic obstructive pulmonary disease (COPD), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Frequency of moderate or severe acute exacerbation at 52 weeks. Started Aug 2019; status: completed.
02
Drugs
umifenovir
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03851991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851991.